RAP-219’s Long Half-Life and Solid Balance Sheet Make RAPP a High-Reward Long Trade
Rapport Therapeutics is positioned to build a differentiated epilepsy franchise around RAP-219. A long apparent half-life supports sustained AMPA receptor occupancy, which could translate to durable seizure control with a favorable tolerability profile. With a market cap near $2.3B, no debt, and roughly $100M+ in cash after a 2025 financing, the se…